Drugs / Chiglitazar
Chiglitazar
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07511010 | Oct 2026 expected | type 2 diabetes mellitus | Chipscreen Biosciences, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06737523 | Mar → Dec 2025 overdue | acute myeloid leukemia | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 1 | NCT05681273 | Feb → Mar 2023 | type 2 diabetes mellitus | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05515445 | Dec 2022 → Aug 2023 | — | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05515458 | Nov 2022 → Jul 2023 | impaired renal function disease | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05760677 | Oct 2022 → Sep 2023 | polycystic ovary syndrome, type 2 diabetes mellitus | Affiliated Hospital of Nantong University | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07303803 | Jan 2026 → Dec 2030 expected | metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT05193916 | Mar 2022 → Jan 2024 | metabolic dysfunction-associated steatohepatitis | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06125587 | Nov 2023 → Oct 2024 | polycystic ovary syndrome | Shengjing Hospital | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04807348 | Jul 2021 → Feb 2023 | type 2 diabetes mellitus | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02173457 | Sep 2014 → Jan 2017 | type 2 diabetes mellitus | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02121717 | Jun 2014 → Nov 2017 | type 2 diabetes mellitus | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07558525 | Apr 2026 → Dec 2028 expected | prediabetes syndrome | Second Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| — | NCT06773221 | Feb 2025 → Jan 2028 expected | cirrhosis of liver, metabolic dysfunction-associated steatotic liver disease | Beijing Friendship Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06191328 | Jan 2024 → Jun 2025 | diabetes mellitus | Yufan Wang | Unknown | No outcome recorded |
| — | NCT06007014 | Oct 2023 → Oct 2025 | — | Yanbing Li | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chiglitazar | “Chiglitazar Sodium in combination with Venetoclax and Azacitidine” NCT06737523 ↗ |
| Known as | Carfloglitazar | “Chiglitazar (Carfloglitazar) is a novel non-thiazolidinedione (TZD) structured” PMID 36654286 ↗ Mar 2021 |
| Known as | Chiglitazar Sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07558525 ↗ |
| Action | Activate | “peroxisome proliferator-activated receptor (PPAR) pan-agonist” PMID 36654286 ↗ Mar 2021 |
| Route | Oral | “Take orally” NCT02121717 ↗ |